EP3787756A1 - Topische verwendung von ölsamen von mindestens einem doldenblütler für eine lindernde wirkung auf die reaktive haut - Google Patents

Topische verwendung von ölsamen von mindestens einem doldenblütler für eine lindernde wirkung auf die reaktive haut

Info

Publication number
EP3787756A1
EP3787756A1 EP19728485.4A EP19728485A EP3787756A1 EP 3787756 A1 EP3787756 A1 EP 3787756A1 EP 19728485 A EP19728485 A EP 19728485A EP 3787756 A1 EP3787756 A1 EP 3787756A1
Authority
EP
European Patent Office
Prior art keywords
oil
radical
skin
agents
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP19728485.4A
Other languages
English (en)
French (fr)
Inventor
Catherine KERN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Societe dExploitation de Produits pour les Industries Chimiques SEPPIC SA
Original Assignee
Societe dExploitation de Produits pour les Industries Chimiques SEPPIC SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Societe dExploitation de Produits pour les Industries Chimiques SEPPIC SA filed Critical Societe dExploitation de Produits pour les Industries Chimiques SEPPIC SA
Publication of EP3787756A1 publication Critical patent/EP3787756A1/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
    • A61K8/922—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of vegetable origin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/37—Esters of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A61K8/9789—Magnoliopsida [dicotyledons]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/005—Preparations for sensitive skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/87—Application Devices; Containers; Packaging

Definitions

  • the present invention relates to the use of at least one seed oil of an umbelliferous plant to prevent or slow the onset of dysaesthesic sensations on human sensitive skin.
  • the skin is the first barrier of protection of the body vis-à-vis the environment. It therefore undergoes many external aggressions that can lead to skin reactions of discomfort or even, in the case of very intense or more serious reactions, skin irritation and / or inflammation. Skin discomfort reactions can be induced by contact with chemicals such as cleansers, perms, hair coloring or from mechanical actions such as shaving, exfoliation, peeling, hair removal. , or come from the action of temperature, climate, ultraviolet radiation or even air pollution.
  • Sensitive or reactive skin is particularly exposed to the consequences of these external aggressions. Sensitive or reactive skin is a condition that affects many people: about 50% of people (60% of women, 40% of men) report having reactive skin. It was recently defined as "a syndrome defined by the appearance of unpleasant sensations (tingling sensations, burning, pain, pruritus and tingling) in response to stimuli that normally should not cause such sensations. sensations can not be explained by lesions related to skin diseases. The skin may look normal or present in addition to erythema.Sensitive skin can affect all areas of the body, especially the face "(1) .
  • TRPA1 is involved in a number of physiological and cellular processes in humans, including nociception, particularly in response to chemical irritants, itching / pruritus, neurogenic inflammation and thermosensation (5).
  • TRPA1 is involved in transmitting histamine-independent itch sensations to the central nervous system.
  • TRPA1 has also been implicated in the cycles of itching / scratching caused in dry skin, which is consistent with the fact that TRPA1 is an essential sensor of skin barrier aggression (6).
  • the appearance of signs of discomfort, within minutes of contacting the subject with the triggering element, is one of the essential features of sensitive skin with neurosensory dysfunction.
  • dysaesthetic sensations are meant more or less painful sensations felt in a cutaneous area such as tingling, tingling, itching, burning, heating, discomfort, tightness.
  • the cosmetic and / or dermatological and / or nutritional compositions that can be used to prevent or slow the onset of dysaesthesic sensations on sensitive skin, and more particularly tingling, tingling, itching, tugging, can be administered by oral or topically.
  • They generally comprise fatty phases consisting of at least one oil of plant, animal, mineral or synthetic origin.
  • vegetable oils are widely used because the trend of the market is oriented towards the use of products from the natural world.
  • Vegetable oils consist mainly of triglycerides, which are distinguished by different types of fatty chains and which, after glycerolysis, provides access to a characteristic fatty carboxylic acid distribution.
  • Vegetable oils are therefore distinguished from essential oils of plants because essential oils are odoriferous products obtained from a plant material, usually by steaming. An essential oil extracted from a plant can therefore not contain fatty triglycerides.
  • petroselinic acid or (Z) -octadec-6-enoic acid is known for its use in the treatment or prophylaxis of diseases of the skin or scalp .
  • the international patent application published under the number WO 99/02149 A1 describes in particular use against inflammation related to psoriasis, erythema (sunburn), eczema, seborrheic dermatitis, alopecia a reata, mycosis , acne or other dermatoses, for example.
  • Petroselinic acid is more particularly present in oils from an umbellifer, a plant whose flowers are arranged in umbels.
  • coriander has been used as an ingredient in the traditional Ayurvedic cosmetic formula (Varnakarlepa) to normalize skin color (7).
  • the described effects relate to the essential oil of coriander, and not the coriander seed oil (8).
  • coriander essential oil is described for these inflammatory effects (9).
  • Coriander seed powder showed an anti-inflammatory effect in vivo in an inflammatory model of carrageenan-induced edema in rats (10). While coriander oil showed an anti-radical effect in tubo, it did not show any anti-inflammatory effect in the same in vivo model as previously (11).
  • the coriander extracts obtained by extraction with hexane or methanol, showed in vitro activity on the inhibition of the enzymes cycloxygenase-1 and -2 (13). Nevertheless, the signaling pathways involved between cyclooxygenases / lipoxygenases on the one hand and the activation of sensory neurons on the other hand are not correlated, and no effect on the sensations of itching, pruritus or discomfort have have been observed or demonstrated.
  • EP0888773 A1 The European patent application published under the number EP0888773 A1 relates to the use of petroselinic acid for the treatment of superficial tissue inflammations, in particular for the preparation of a composition intended to activate the peroxisomal b-oxidation of fatty acids. in the superficial tissues of a mammal so as to be able to treat or prevent inflammation and / or modulate the lipid metabolism of the superficial tissues has been abandoned because of a state of the art deemed too important. But nothing in EP0888773 A1 discloses the use of coriander seed oil to prevent and / or reduce the sensations of discomfort resulting from sensitive or reactive skin, and in particular the sensations of itching, pruritus, tingling, tingling, itching, tugging.
  • US6365175 relates to the use of petroselinic acid in the food field, and in particular to prepare dietary supplement compositions used as anti-inflammatory compositions that inhibit the production of acid metabolites. arachidonic and / or reduce the formation of intracellular adhesion molecules or anti-aging compositions. But nothing in US6365175 discloses or teaches the use of coriander seed oil to prevent and / or lessen the sensations of discomfort resulting from sensitive or reactive skin, and particularly the sensations of itching, pruritus, tingling, tingling, itching, tugging.
  • the inventor focused on developing a new composition with positive effects on sensitive skin.
  • the subject of the invention is a use of at least one seed oil of at least one umbelliferous plant as a cosmetic active ingredient.
  • disaesthetic sensations is understood to mean sensations felt in a cutaneous zone, such as tingling, tingling, itching, burning, heating, tugging.
  • the seed oils of such umbelliferous plants are obtained by the implementation of a process comprising at least one step of grinding the seeds and / or at least one step of pressing the seeds, and at least one subsequent step of refining the liquid. oily obtained after the grinding and / or pressing step.
  • coriander seed oil It is preferable to use coriander seed oil.
  • the use according to the invention may have one or more of the following characteristics:
  • the umbelliferous plant is chosen from coriander, chervil, celery, caraway, carrot, dill, parsley and fennel,
  • the umbelliferous plant is coriander
  • the seed oil of an umbelliferous plant comprises, for 100% of its mass, a mass proportion of at least one triglyceride greater than or equal to 99%, with the triglyceride being a compound of formula (I):
  • the seed oil of an umbelliferous plant comprises for 100% of the mass of triglycerides of formula (I): a mass quantity of between 2% and 5% of a triglyceride of formula
  • the present invention also relates to a cosmetic or dermatological formulation for topical use comprising for 100% of its mass:
  • cosmetic formulation for topical use means according to the directive of the Council of the Community Economic European N ° 76/768 / CEE of July 27, 1976 modified by the directive n ° 93/35 / CEE of June 14, 1993, that said formulation includes any substance or preparation intended to be put in contact with the various parts of the human body (epidermis, hair and hair system, nails, lips and genitals) or with the teeth and oral mucosa in view, exclusively and mainly, to clean, perfume, modify the appearance and / or correct body odor and / or protect or maintain it in good condition.
  • the formulation according to the invention may have one or more of the following characteristics:
  • an aqueous or hydro-alcoholic or hydro-glycolic solution in the form of a suspension, an emulsion, a microemulsion or a nanoemulsion, whether of water-in-oil, oil-in-water, water-in-oil-in-water or oil-in-water-in-oil type, or in the form of a powder.
  • the cosmetically acceptable ingredient is an excipient and / or an active ingredient.
  • the excipient and / or the active ingredient are chosen from thickening and / or gelling surfactants, stabilizers, film-forming compounds, hydrotropic agents, plasticizing agents, emulsifying and co-emulsifying agents, opacifying agents, agents nacrants, superfatting agents, sequestering agents, chelating agents, antioxidants, perfumes, preservatives, conditioners, bleaching agents for hair and skin discoloration, active principles for providing a treating action against for the skin or hair, sunscreens, mineral fillers or pigments, particles providing a visual effect or intended for the encapsulation of active ingredients, exfoliating particles and texture agents.
  • foaming and / or detergent surfactants which may be combined with the topical formulation of the present invention as defined above include anionic, cationic, amphoteric or nonionic foaming and / or detergent surfactants.
  • foaming and / or detergent anionic surfactants that can be combined with the formulation for topical use that is the subject of the present invention as defined above, mention may be made of the alkali metal, alkaline earth metal, ammonium, amine or alkylalcohol salts of alkylether sulfates, of alkyl sulphates,
  • alkylamidoether sulphates alkylaryl polyethersulfates, monoglyceride sulphates, alphaolefin sulphonates, paraffin sulphonates, alkyl phosphates, alkyl ether phosphates, alkyl sulphonates, alkylamide sulphonates, alkylaryl sulphonates, alkyl carboxylates, alkyl sulphosuccinates, alkyl ether sulphosuccinates, alkylamide sulphosuccinates, alkyl sulphoacetates, alkyl sarcosinates, acyl isethionates, N-acyl ta urines, acyl lactylates, N-acyl derivatives amino acids, N-acyl derivatives of peptides, N-acyl derivatives of proteins, N-acyl derivatives of fatty acids.
  • foaming and / or detergent amphoteric surfactants that may be associated with the topical formulation of the present invention as defined above, mention may be made of alkyl betaines, imidazolines, phosphobetaines, amphopolyacetates and amphopropionates.
  • foaming and / or detergent cationic surfactants that may be associated with the formulation for topical use that is the subject of the present invention as defined above, mention may be made especially of quaternary ammonium derivatives.
  • alkylpolyglycosides comprising an aliphatic radical, linear or branched, saturated or unsaturated, and having from 8 to 16 carbon atoms, such as octyl polyglucoside, decyl polyglucoside, undecylenyl polyglucoside, dodecyl polyglucoside, tetradecyl polyglucoside, hexadecyl polyglucoside, 1-12 dodecanediyl polyglucoside; ethoxylated hydrogenated castor oil derivatives such as the product marketed under the INCI name "Peg-40 hydrogenated castor oil”; polysorbates such as Polysorbate 20, Polysorbate 40, Polysorbate 60, Polysorbate 70, Polysorbate 80, Polysorbate 85; coconut amides; N-alkylamines.
  • thickening and / or gelling surfactants that may be combined with the formulation for topical use that is the subject of the present invention as defined above include fatty esters of alkylpolyglycosides that are optionally alkoxylated, such as ethoxylated methylpolyglucoside esters such as that PEG 120 methyl glucose trioleate and PEG 120 methyl glucose dioleate respectively marketed under the names GLUCAMATE TM LT and G LU MATE TM DOE120; alkoxylated fatty esters such as PEG 150 pentaerythritol tetrastearate sold under the name CROTHIX TM
  • thickening and / or gelling agents that may be associated with the formulation for topical use that is the subject of the present invention as defined above, mention may be made of the co-polymers of AMPS and of alkyl acrylates of which the carbon chain comprises between four and thirty carbon atoms and more particularly between ten and thirty carbon atoms, the linear, branched or crosslinked terpolymers of at least one monomer having a strong, free, partially salified or totally salified acid function, with at least one neutral monomer, and at least one monomer of formula (XIII): ## STR2 ##
  • R'3 represents a hydrogen atom or a methyl radical
  • R'4 represents a linear or branched alkyl radical containing from eight to thirty carbon atoms
  • polysaccharides consisting solely of monosaccharides, such as glucans or homopolymers of glucose. , glucomannoglucans, xyloglycans, galactomannans whose degree of substitution (DS) of D-ga lac
  • thickening and / or gelling agents that can be combined with the formulation for topical use that is the subject of the present invention as defined above include polysaccharides consisting of monosaccharides, such as sulphated galactans, and more especially carrageenans and agar, uronans and more particularly algin, alginates and pectins, heteropolymers of oses and uronic acids and more especially xanthan gum, gellan gum, exudates of gum arabic and karaya gum, glucosaminoglycans.
  • monosaccharides such as sulphated galactans, and more especially carrageenans and agar
  • uronans and more particularly algin, alginates and pectins heteropolymers of oses and uronic acids and more especially xanthan gum, gellan gum, exudates of gum arabic and karaya gum, glucosaminoglycans.
  • thickening agents and / or gelling agents that can be associated with the topical formulation object of the present invention as defined above, include cellulose, cellulose derivatives such as methyl cellulose, ethyl cellulose, hydroxypropyl cellulose, silicates, starch, hydrophilic derivatives of starch, polyurethanes.
  • stabilizing agents examples include microcrystalline waxes, and more particularly ozokerite, mineral salts such as sodium or magnesium chloride, silicone polymers such as polysiloxane polyalkyl polyether co polymers.
  • solvents that may be associated with the formulation for topical use object of the present invention as defined above, mention may be made of water, organic solvents such as glycerol, diglycerol, oligomers of glycerol, ethylene glycol, propylene glycol, butylene glycol, 1,3-propanediol, 1,2-propanediol, hexylene glycol, diethylene glycol, xylitol, erythritol, sorbitol, water-soluble alcohols such as ethanol , isopropanol or butanol, water mixtures and said organic solvents.
  • organic solvents such as glycerol, diglycerol, oligomers of glycerol, ethylene glycol, propylene glycol, butylene glycol, 1,3-propanediol, 1,2-propanediol, hexylene glycol, diethylene glycol, xylitol, erythritol
  • thermal or mineral waters having a mineralization of at least 300 mg / l, especially Avene water, Vittel water, Vichy basin water, Uriage water, Roche Posay water, Bourboule water, Enghien water -the-baths, the water of Saint-Gervais-les Bains, the water of Néris-les-Bains, the water of Allevard-les-Bains, the water of Digne, the water of the Maizieres, the Neyrac-les-Bains water, Lons le Saunier water, Rochefort water, Saint Christau water, Fumades water and Tercis-les-Bains water.
  • hydrotropic agents that can be associated with the composition (CE) for topical use object of the present invention as defined above, there may be mentioned xylenesulfonates, cumenesulfonates, hexylpolyglucoside, 2-ethylhexylpolyglucoside n-heptylpolyglucoside.
  • emulsifying surfactants which may be associated with the formulation for topical use object of the present invention as defined above, there may be mentioned nonionic surfactants, anionic surfactants, cationic surfactants.
  • esters of fatty acids and of sorbitol such as the products sold under the names MONTANE TM 40, MONTANE TM 60, MONTANE TM 70, MONTANE TM 80 and MONTANE TM 85; compositions comprising glycerol stearate and ethoxylated stearic acid between 5 moles and 150 moles of ethylene oxide, such as the composition comprising stearic acid ethoxylated with 135 moles of ethylene oxide and glycerol stearate. marketed under the name SIMULSOL TM 165; mannitan esters; ethoxylated mannitan esters; sucrose esters; esters of
  • alkylpolyglycosides comprising a linear or branched, saturated or unsaturated aliphatic radical containing from 14 to 36 carbon atoms, for instance tetradecyl polyglucoside, hexadecyl polyglucoside, octadecyl polyglucoside, hexadecylpolyxyloside or octadecylpolyxyloside, eicosyl polyglucoside, dodecosyl polyglucoside, 2-octyldodecyl polyxyloside, 12-hydroxystearyl polyglucoside; linear or branched fatty alcohol compositions, saturated or unsaturated, and containing from 14 to 36 carbon atoms, and alkylpolyglycosides as described above, for example the compositions sold under the names MONTANOV TM 68, MONTANOV TM 14, MONTANOV TM 82,
  • anionic surfactants which may be associated with the formulation for topical use object of the present invention as defined above, mention may be made of glyceryl stearate citrate, cetearyl sulphate, soaps such as sodium stearate or triethanolammonium stearate. N-acyl derivatives of salified amino acids, for example stearoyl glutamate.
  • emulsifying cationic surfactants which may be combined with the topical formulation of the present invention as defined above include aminoxides, quaternium-82 and the surfactants described in patent application WO96 / 00719. and mainly those whose fatty chain comprises at least 16 carbon atoms.
  • Examples of opacifying and / or nacrating agents that may be associated with the topical formulation of the present invention as defined above include sodium palmitate, sodium stearate, sodium hydroxystearate , magnesium palmitate, magnesium stearate, magnesium hydroxystearate, ethylene glycol monostearate, ethylene glycol distearate, polyethylene glycol monostearate, polyethylene glycol distearate, fatty alcohols having from 12 to 22 carbon atoms.
  • Examples of texturizing agents which may be associated with the formulation for topical use that is the subject of the present invention as defined above include N-acylated derivatives of amino acids, such as lauroyl lysine marketed under the present invention.
  • alkali silicates such as zinc sulfate, zinc gluconate, zinc chloride, zinc lactate; quaternary ammonium salts such as cetyltrimethylammonium salts, cetylpyridinium salts; glycerol derivatives such as glycerol caprate, glycerol caprylate, polyglycerol caprate; 1,2 decanediol; 1,3 propanediol; salicylic acid; sodium bicarbonate; cyclodextrins; metallic zeolites; TRICLOSAN TM; aluminum bromohydrate, aluminum chlorohydrates, aluminum chloride, aluminum sulphate, aluminum and zirconium hydrochlorides, aluminum and zirconium trihydrochloride, aluminum zirconium tetrachlorohydrate , aluminum and zirconium pentachlorohydrate, aluminum and
  • oils which can be associated with the formulation for topical use object of the present invention as defined above, mention may be made of mineral oils such as paraffin oil, vaseline oil, isoparaffins or mineral white oils; oils of animal origin, such as squalene or squalane; vegetable oils, such as phytosqualane, sweet almond oil, coconut oil, castor oil, jojoba oil, olive oil, rapeseed oil, peanut oil, sunflower oil, wheat germ oil, corn germ oil, soybean oil, cottonseed oil, alfalfa oil, poppy oil , pumpkin oil, evening primrose oil, millet oil, barley oil, rye oil, safflower oil,nadooulier oil, passionflower oil , hazelnut oil, palm oil, shea butter, apricot kernel oil, calophyllum oil, sysymbrium oil, avocado oil, calendula, oils derived from flowers or vegetables vegetable oils ethoxylated; synthetic oils such as fatty acid esters such as butyl myr
  • waxes that can be associated with the formulation for topical use object of the present invention as defined above, include beeswax, carnauba wax, candelilla wax, wax ouricoury , Japanese wax, cork fiber wax, sugar cane wax, paraffin waxes, lignite waxes, microcrystalline waxes, lanolin wax; ozokerite; polyethylene wax; silicone waxes; vegetable waxes; fatty alcohols and solid fatty acids at room temperature; glycerides solid to ambient temperature.
  • waxes is meant in the present application compounds and / or mixtures of water-insoluble compounds having a solid appearance at a temperature greater than or equal to 45 ° C.
  • Examples of active principles that can be associated with the formulation for topical use object of the present invention as defined above include vitamins and their derivatives, including their esters, such as retinol (vitamin A) and its esters (retinyl palmitate, for example), ascorbic acid (vitamin C) and its esters, ascorbic acid sugar derivatives (such as ascorbyl glucoside), tocopherol (vitamin E) and its esters (as tocopherol acetate), vitamins B3 or B10 (niacinamide and its derivatives); compounds showing a lightening or depigmenting action on the skin, such as w-undecelynoyl phenylalanine marketed under the name SEPIWHITE TM MSH, SEPICALM TM VG, the mono ester and / or the glycerol diester of w-undecelynoyl phenylalanine, the w- undecelynoyl dipeptides, arbutin, kojic
  • antioxidants that can be associated with the formulation for topical use object of the present invention as defined above, mention may be made of EDTA and its salts, citric acid, tartaric acid, oxalic acid, BHA (butylhydroxyanisol), BHT (butylhydroxytoluene), tocopherol derivatives such as tocopherol acetate, mixtures of antioxidant compounds such as DISSOLVINE GL 475 marketed by Akzo Nobel under the name INCI: Tetrasodium glutamate
  • sunscreens that can be associated with the formulation for topical use object of the present invention as defined above, we can cite all those appearing in the cosmetic directive 76/768 / EEC modified Annex VII.
  • the solar organic filters that can be associated with the formulation for topical use object of the present invention as defined above, include the family of benzoic acid derivatives such as para-aminobenzoic acids (PABA), including the monoglycerol esters of PABA, the ethyl esters of N, N25 propoxy PABA, the ethyl esters of N, N-diethoxy PABA, the ethyl esters of N, Ndimethyl PABA, the methyl esters of N, N-dimethyl PABA, the esters butyl N, Ndimethyl PABA; the family of anthranilic acid derivatives such as homomenthyl-N-acetyl anthranilate; the family of salicylic acid derivatives such as amyl salicylate, homomenthyl salicylate, ethylhexyl salicylate, phenyl salicylate, benzyl salicylate, p-isopropanolphenyl salicylate; the family of
  • inorganic screens which may be associated with the formulation for topical use object of the present invention as defined above, include titanium oxides, zinc oxides, cerium oxide, zirconium oxide, iron oxides yellow, red or black, chromium oxides. These inorganic screens may or may not be micronized, have undergone or not surface treatments and may be presented in the form of aqueous or oily pre-dispersions.
  • the present invention also relates to a method for preventing or slowing the appearance of dysaesthesic sensations on human sensitive skin comprising at least one step a) of applying to the surface of the skin to be treated with an effective amount of the formulation cosmetic as defined above.
  • an amount is meant in the definition of the method as defined above, an amount such that the slowing of dysaesthesic sensations on human skin shows an increase of at least 25% compared to the rate measured before the application of the formulation as defined above, on the surface of the epidermis of the skin to be treated, after a period of between seven days and twenty-one days after the application of said formulation on said surface of the epidermis treat.
  • this method comprises a step b) of massage of the surface of the treated skin.
  • formulation as defined above for use in a therapeutic treatment intended to prevent or slow the onset of dysaesthesic sensations on human sensitive skin.
  • TR P A1 receptor activation
  • Human sensory neurons were obtained from pluripotent stem cells and grown in culture plates. Human keratinocytes were amplified and seeded above the neurons. After 19 days of co-culture at 37 ° C., in a humid atmosphere at 5% CO 2, the products under test or the positive reference, HC030031 (C18H21N503), at 10 mM, as well as the fluorescent probe Fluo-4 AM, were added to the co-culture.
  • the Fluo-4 AM probe tracks the rapid kinetics of variation in intracellular calcium concentration by measuring its fluorescence intensity in real time and the calcium flux is associated with the activation of TRPA1.
  • the culture medium was removed, the cultures were washed and then incubated again with the products under test. Immediately thereafter, they were placed under an inverted microscope and observed epi-fluorescence. The cells were observed for 3 minutes, a photograph was taken approximately every 333 ms. Five seconds after the start of the recording, the neurons were stimulated with AITC (allyl isothiocyanate) 10-3 M.
  • AITC allyl isothiocyanate
  • % stimulation 100 x [average (condition)] / [average (cells stimulated with AITC)]
  • % protection 100 x [average (condition) - average (cells stimulated with TIAC)] / [average (unstressed cells) - average (cells stimulated with TIAC)].
  • HC30031 a TR P A1 antagonist, significantly reduced TRPA1 activation by 88%.
  • coriander seed oil also significantly reduced TRPA1 activation by 61%.
  • the coriander seed oil is able to reduce the activation of TRPA1 in a keratinocyte-human neuron co-culture model.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Birds (AREA)
  • Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Emergency Medicine (AREA)
  • Cosmetics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
EP19728485.4A 2018-05-04 2019-05-02 Topische verwendung von ölsamen von mindestens einem doldenblütler für eine lindernde wirkung auf die reaktive haut Withdrawn EP3787756A1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1853880A FR3080770B1 (fr) 2018-05-04 2018-05-04 Utilisation topique d'huile de graines d'au moins une plante ombellifere pour un effet apaisant des peaux reactives
PCT/FR2019/051012 WO2019211563A1 (fr) 2018-05-04 2019-05-02 Utilisation topique d'huile de graines d'au moins une plante ombellifère pour un effet apaisant des peaux réactives

Publications (1)

Publication Number Publication Date
EP3787756A1 true EP3787756A1 (de) 2021-03-10

Family

ID=63683979

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19728485.4A Withdrawn EP3787756A1 (de) 2018-05-04 2019-05-02 Topische verwendung von ölsamen von mindestens einem doldenblütler für eine lindernde wirkung auf die reaktive haut

Country Status (6)

Country Link
EP (1) EP3787756A1 (de)
JP (1) JP2021522287A (de)
KR (1) KR20210003865A (de)
CN (1) CN112236200A (de)
FR (1) FR3080770B1 (de)
WO (1) WO2019211563A1 (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102592171B1 (ko) * 2022-10-28 2023-10-20 주식회사 제이투케이바이오 회향씨, 소두구씨, 고수, 샤프란꽃의 복합 추출물을 함유하는 피부 쿨링용 화장료 조성물

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2721607B1 (fr) 1994-06-28 1996-10-31 Seppic Sa Nouveaux dérivés d'ammoniums quaternaires, leur procédé de préparation et leur utilisation comme agents de surface.
FR2725370B1 (fr) * 1994-10-07 1997-06-06 Oreal Composition cosmetique ou dermatologique contenant une huile riche en acide petroselinique
FR2761595B1 (fr) 1997-04-04 1999-09-17 Oreal Compositions comprenant des santalines, santarubines pour la coloration artificielle de la peau et utilisations
EP0888773A1 (de) * 1997-07-05 1999-01-07 Societe Des Produits Nestle S.A. Verwendung von Petroselinsäure zur Behandlung von Entzündungen der oberflächlichen Gewebe
ES2248962T5 (es) 1998-12-22 2010-01-04 Unilever N.V. Uso cosmetico del acido petroselenico.
GB9918030D0 (en) * 1999-07-30 1999-09-29 Unilever Plc Skin care composition
CA2487945A1 (fr) 2002-06-11 2003-12-18 L'oreal Utilisation d'un agent mimetique de l'activite de la dopachrome tautomerase (trp-2) comme agent protecteur des melanocytes du follicule pileux et applications
CA2747845C (en) * 2005-12-14 2012-10-09 Zars Pharma, Inc. Compositions and methods for dermally treating pain
PT1932510E (pt) * 2006-12-14 2016-06-16 Oreal Utilização de pelo menos um ácido gordo monoinsaturado para o tratamento das peles, das mucosas e dos couros cabeludos frágeis
WO2013073801A1 (ko) * 2011-11-18 2013-05-23 한국식품연구원 hTRPA1 활성화 조성물 및 그의 용도

Also Published As

Publication number Publication date
KR20210003865A (ko) 2021-01-12
CN112236200A (zh) 2021-01-15
WO2019211563A1 (fr) 2019-11-07
FR3080770B1 (fr) 2020-09-18
JP2021522287A (ja) 2021-08-30
FR3080770A1 (fr) 2019-11-08

Similar Documents

Publication Publication Date Title
EP3773443A1 (de) Verwendung einer neuen zusammensetzung zur vorbeugung oder verlangsamung des auftretens von anzeichen einer entzündung
EP3261727B1 (de) Gewinnung eines extrakts aus gametophyten aus braunen algen und verwendung des besagten extrakts als kosmetischer anti-aging-wirkstoff
EP3474954B1 (de) Verfahren zur herstellung eines mit diglycosid angereicherten armeria-maritima-extrakts und dessen verwendung in der kosmetik
EP3209277A1 (de) Verwendung von isosorbidester und n-acylierten aminosäurederivaten als alterungsschutzmittel für die menschliche haut
EP3452007A1 (de) Verfahren zur kurzfristigen verbesserung des feuchthaltungszustands der epidermis der menschlichen haut, neuartige feuchthaltungszusammensetzungen
EP3787756A1 (de) Topische verwendung von ölsamen von mindestens einem doldenblütler für eine lindernde wirkung auf die reaktive haut
EP3212615B1 (de) Verwendung von estern des n-acylierten derivaten von aminosäuren und polyolen als antialterungsmittel für menschliche haut
EP3723719B1 (de) Neue glycerylpolyrhamnoside, verfahren zur herstellung davon und kosmetische und/oder pharmazeutische zusammensetzungen damit
EP3723720B1 (de) Neue polyolpolyrhamnoside, verfahren zu ihrer herstellung sowie kosmetische und/oder pharmazeutische zusammensetzungen damit
EP3773930A1 (de) Verwendung einer neuen zusammensetzung zur verhinderung oder verlangsamung des auftretens von unschönen anzeichen in bezug auf das vorhandensein von überschüssigem talg
FR3029108A1 (fr) Utilisation d'esters de alpha, omega-alcanediols et de derives n-acyles d'acide amines, comme agent eclaircissant de la peau humaine
FR3027517A1 (fr) Composition de mono-ester et de diester de la n-alkyl phenylalanine et de l'isosorbide, procede pour sa preparation et son utilisation comme agent eclaircissant de la peau
FR3029411A1 (fr) Utilisation d'esters avec le 1,3-butanediol de derives n-acyles d'acide amines, comme agent eclaircissant de la peau humaine
FR3029104A1 (fr) Utilisation d'esters de alpha,omega-diols et de derives n-acyles d'acides amines comme agent de brunissage et/ou de bronzage de la peau humaine
FR3027519A1 (fr) Utilisation d'esters d'isosorbide et de derives n-acyles d'acides amines comme agent de brunissage et/ou de bronzage de la peau humaine
FR3027515B1 (fr) Utilisation d'esters de la phenylalanine et de polyols comme agent eclaircissant de la peau du corps humain
WO2024194370A1 (fr) Extrait d' himanthalia elongata, composition cosmétique en comprenant, et ses utilisations
FR3085839A1 (fr) Utilisation de phytosterols
FR3029105A1 (fr) Utilisation d'esters de alpha, omega-alcanediols et de derives n-acyles d'acide amines, comme agent antivieillissement de la peau humaine
FR3029412A1 (fr) Utilisation de derives n-acyles d'acide amines esterifies avec le 1,3-butanediol, comme agent antivieillissement de la peau humaine
FR3029410A1 (fr) Utilisation d'esters de 1,3-butanediol et de derives n-acyles d'acides amines comme agent de brunissage et/ou de bronzage de la peau humaine
FR3027516A1 (fr) Utilisation d'esters de polyols et de derives n-acyles d'acides amines comme agent propigmentant de la peau humaine des cheveux et des poils.

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20201204

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20211005

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20231031